Darwin Global Management »

Ambrx Biopharma shares owned by Darwin Global Management

Quarter-by-quarter ownership of Ambrx Biopharma shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Ambrx Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Ambrx Biopharma held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ambrx Biopharma by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $238M 17M 14.24

More positions owned by Darwin Global Management

Ambrx Biopharma
Tg Therapeutics (TGTX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Vaxcyte (PCVX)
Springworks Therapeutics (SWTX)
Nuvalent Inc-a (NUVL)

View all positions for Darwin Global Management

Top funds holding Ambrx Biopharma

Darwin Global Management
Cormorant Asset Management
Paradigm Biocapital Advisors
D. E. Shaw & Co
Nextech Invest
Balyasny Asset Management
Citadel Advisors
Logos Global Management
VR Adviser
Vanguard Group
T. Rowe Price Associates
Millennium Management
Goldman Sachs Group
Federated Investors
OrbiMed Advisors

View all funds holding Ambrx Biopharma